UCB (OTCMKTS:UCBJY) Stock Price Crosses Below 200 Day Moving Average – Should You Sell?
UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $95.59 and traded ...
Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade)
Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...
MPR2d
FDA Drug Approval Decisions Expected in May 2025
The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.
Medscape3d
Two Oral TYK2 Inhibitors Enter Phase 3 Trials for Plaque Psoriasis on Basis of Phase 2 Promise
Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...
Medscape5d
Non-Pharmacologic Therapies in Psoriasis and Psoriatic Arthritis: 5 Things to Know
While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...